Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe

This publication has 29 references indexed in Scilit:

• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
  The Lancet, 2010
• Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance
  Clinical Chemistry and Laboratory Medicine (CCLM), 2010
• Rosuvastatin reduces neointima formation in a rat model of balloon injury
  European Journal of Medical Research, 2010
• Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
  The Lancet, 2009
• Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
  American Heart Journal, 2008
• Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years
  International Journal Of Clinical Practice, 2008
• Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2
  Cardiovascular Research, 2008
• Direct Demonstration of an Antiinflammatory Effect of Simvastatin in Subjects with the Metabolic Syndrome
  The Journal of Clinical Endocrinology & Metabolism, 2006
• Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia
  Circulation, 2003
• Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption
  Journal of Medicinal Chemistry, 1998